• Mitsubishi Tanabe Pharma Canada Announces ^prRADICAVA^® (Edaravone) Oral Suspension Is Now Available in Canada for the Treatment of Patients with ALS
  

  ---

• ^prRADICAVA^® (Edaravone) Oral Suspension Receives Positive Recommendation from CADTH for the Treatment of Patients with ALS
  

  ---

• ^prRADICAVA^® (Edaravone) Oral Suspension Receives Positive Recommendation from INESSS for the Treatment of Patients With ALS
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of ^prRADICAVA^® (Edaravone) Oral Suspension for the Treatment of Patients with ALS
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces Publication of Real-World Data for Radicava^® (Edaravone)
  

  ---

• Health Canada Accepts SNDS Filing and Grants Priority Review for Oral Edaravone Formulation for the Treatment of ALS
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces That Treatment for Amyotrophic Lateral Sclerosis (ALS) Is Now Available Through Newfoundland and Labrador Prescription Drug Program
  

  ---

• MTP-CA Applauds the Release of Canada’s First ALS Management Guidelines
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) Now Eligible for Coverage Through Veterans Affairs Canada and Indigenous Services Canada
  

  ---